Press Releases Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Real-time Estimate Tradegate Other stock markets 03:47:30 08/05/2024 pm IST			5-day change	1st Jan Change
1.953 ^EUR	+0.05%		+2.30%	+3.50%

06/05	Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
22/04	Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oryzon Genomics S A : reports financial results and corporate update for quarter ended March 31, 2024	06/05	PU
Oryzon Genomics S A : secures another important patent for its lead CNS asset, vafidemstat	22/04	PU
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	08/04	AQ
Oryzon Genomics S A : to provide corporate progress updates at several events in April	05/04	PU
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023	27/02	AQ
ORYZON to Provide Corporate Progress Updates at Several Events in February-March	05/02	AQ
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024	19/01	AQ
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)	06/01	AQ
ORYZON to Provide Corporate Progress Updates at Several Events in January	03/01	AQ
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.	04/12	AQ
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million	21/11	AQ
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)	07/11	AQ
Oryzon Genomics S A : to provide corporate progress updates at several events in November	06/11	PU
ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023	27/23/27	AQ
Oryzon Genomics S A : presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder	10/23/10	PU
Oryzon Genomics S A : receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies	03/23/03	PU
Oryzon Genomics S A : to provide corporate progress updates at several events in October	02/23/02	PU
ORYZON to Give Updates on Corporate Progress in September	05/23/05	AQ
Oryzon Genomics S A : announces completed patient recruitment in the PORTICO Phase IIb trial of vafidemstat in Borderline Personality Disorder	26/23/26	PU
Oryzon Genomics S A : reports financial results and corporate updates for half-year ending June 30, 2023	24/23/24	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Press Releases

Filters